Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gammagard primary versus secondary infection prophylaxis in multiple myeloma patients receiving teclistamab
2024-518420-80-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Feb 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of kiovig and teclistamab in secondary immunodeficiency (SID), Infection and bacterial disease (2 arms), sponsored by Takeda. Primary endpoint: Time to first serious infection. Planned start Feb 2026; status: authorised.
02
Drugs
kiovigteclistamab
03
Conditions
secondary immunodeficiency (SID)Infectionbacterial disease
Beyond the preview
Go deeper on 2024-518420-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518420-80-00.